Caris Life Sciences (CAI) announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insight. This new signature is designed to predict early platinum resistance in patients with high-grade serous ovarian cancer and provides clinicians with unprecedented molecular insight into how long a patient may benefit from first-line platinum-based chemotherapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $22 from $30 at Canaccord
- Caris Life Sciences Signals Strong Growth and Ambition
- Caris Life Sciences price target raised to $28 from $26 at Baird
- Caris Life Sciences price target lowered to $34 from $38 at Evercore ISI
- Caris Life Sciences price target lowered to $38 from $45 at BTIG